OPTH — Optimi Health Corp.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2027329 ·
Last close
$4.85
Market Cap
$27.29M
52W High
$6.40
52W Low
$4.00
ADV30
98,293
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 99,500 | 89,464 | -1,356,912 | -1,591,871 | 13,509,676 | 106,711 | 9,971,230 |
| Dec 2025 | 0 | 0 | -1,280,597 | -1,553,975 | 14,236,203 | 491,750 | 9,219,190 |
| Sep 2025 | -64,029 | -464,233 | -1,667,227 | -1,349,367 | 15,212,645 | 1,145,065 | 8,641,984 |
| Jun 2025 | 196,389 | 181,933 | -797,781 | -907,318 | 14,135,865 | 88,533 | 6,383,375 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-2,955,900
Investing CF
$-70,129
Financing CF
$3,435,281
CapEx
$-98,759
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-05-21
Balance + Analyst (yfinance extras)
Retained Earnings
$-28,311,788
Inventory
$310,388
Receivables
$118,852
ST Investments
—
EBIT TTM
$-3,304,559
Pretax Income TTM
$-4,007,026
Interest Exp TTM
$702,467
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$231,860
EBITDA
$-3,479,360
Free Cash Flow
$-312,345
Enterprise Value
$33,748,468
Total Cash
$106,711
Total Debt
$6,569,570
Shares Out
5,625,899
Trailing EPS
$-1.23
Book Value
$0.78
ROE
-88.7%
ROA
-20.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 426,301 | -4,612,279 | -3,712,031 | 15,212,645 | 8,641,984 | — | -2,627,901 |
| Sep 2024 | 389,850 | -5,609,185 | -6,035,859 | 14,551,035 | 4,975,323 | — | -4,281,693 |
| Sep 2023 | 181,087 | -5,272,295 | -5,194,548 | 16,491,729 | 3,280,836 | — | -3,601,537 |
| Sep 2022 | 80,717 | -7,389,778 | -7,350,828 | 16,817,771 | 797,665 | — | -4,579,541 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KYNB | KYNTRA BIO, INC. | $27.24M | $6.73 | — |
| RMHI | Retrieve Medical Holdings, Inc. | $27.95M | $1.00 | — |
| ACTU | ACTUATE THERAPEUTICS, INC. | $26.56M | $1.11 | — |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | $26.48M | $0.06 | — |
| ATNM | Actinium Pharmaceuticals, Inc. | $26.26M | $0.84 | — |
News headlines (Yahoo Finance, 1h cache)
3 Psychedelic Stocks With Potential Clinical Trial Catalysts
2026-07-10 06:21 · Yahoo
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
2026-07-06 19:53 · Yahoo
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
2026-06-29 15:13 · Yahoo
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
2026-06-16 16:36 · Yahoo
Why Optimi’s Ibogaine Initiative Could Open a New Growth Channel
2026-06-12 07:34 · Yahoo
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
2026-06-10 18:24 · Yahoo
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
2026-06-08 16:54 · Yahoo
Optimi Health up 2.5% as It Completes Commercial 5mg Psilocybin Production Run
2026-06-02 18:03 · Yahoo
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
2026-06-02 16:36 · Yahoo
Optimi Health (OPTH) Highlights Australia Psychedelic Therapy Expansion Following TGA Framework Update
2026-05-29 19:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.